Company / Cash & Equivalents
Entera Bio Ltd. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$7.1M
FY2025
5-year range
$7.1M / $24.9M
FY2021-FY2025
Trend
-17.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $25M in FY2021 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025 with a 3-year CAGR of -16.7%.
Declined from $11M to $7M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -16.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Entera Bio Ltd.'s cash & equivalents has declined for 4 consecutive years.
- 3-year CAGR of -16.7%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 17.9% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.1M | -17.9% |
| FY2024 | $8.7M | -21.4% |
| FY2023 | $11.0M | -10.5% |
| FY2022 | $12.3M | -50.6% |
| FY2021 | $24.9M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026